Kamari Pharma

Kamari Pharma develops topical and oral drugs based on proprietary small molecules that inhibit the specified TRPV3 ion channel. Kamari Pharma aims to develop innovative treatments for unmet needs in dermatology and rare diseases. These innovative drugs are designed to treat various skin conditions such as keratosis, lichen simplex chronicus, and other severe hereditary skin disorders. The goal is to treat skin conditions with no current treatment options by targeting the root cause of Catt dysfunction.